According to the expression status of ER and HER2 in breast cancer patients and the corresponding treatment (endocrine therapy, anti-HER2 therapy, and chemotherapy), we use the receiver operating characteristics (ROC) plotter (http://www.rocplot.org/) to divide the breast cancer population into therapy responding group and non-responding group based on pathological complete response. This evidence concerns the gene ERBB2 and breast cancer.